National cancer control programmes, pharmaceutical company interest and facilitation of clinical trial participation may be stimulated by epidemiological data
By
Tomohiro Matsuda
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.